Insights

Sepsis is a life-threatening response of the immune system to infection that can lead to tissue damage, organ failure and the risk of permanent disability or death. Detecting and treating it early can be highly effective in stopping progression. The trouble is that implementing the level of monitoring required to catch sepsis at the earliest stages is tough outside critical care settings. 

Patient monitoring is an inherent part of patient management. Intermittent and continuous measurements have a range of uses, from defining disease states and characterising progression to informing therapeutic approaches and...

It could only happen at Cambridge Consultants. An internal training course for a group for engineers eager to gain some understanding of how it is possible to engineer biology. A challenge certainly… but also indicative of the unique blend of biology, engineering and advanced computation that is enabling our breakthrough work in bioinnovation.

Tim Ensor shared his insights from working with a global medical device company to invent deep learning algorithms to amplify clinical trials data by 30x. 

The future of non-contact monitoring: some novel devices which were presented at  CES 2020 for improving health and detecting disease conditions. Many of these were wearables; some are portable. A non-contact monitoring system developed at Cambridge Consultants is described, including a discussion of a range of areas where these technologies could be applied.

Our webinar reveals how device developers will need to maneuver through conservative, highly regulated, monopolistic yet fragmented healthcare systems that often provide contradictory incentives. Following the presentation, our audience had the opportunity to ask a variety of questions. Here’s what our experts had to say in reply.

The recent launch of the Apple Watch Series 4 is the latest example of a device developed by a traditional consumer product company making a well-publicized entry into the patient-facing medical device market. Patient-facing devices...

The rising cost of clinical trials (CTs), coupled with the commercial risks of failure, mean it’s increasingly important to harness the power of real-world data to inform effective trial designs, better understand outcomes and maximise the likelihood of clinical success...

The FDA is changing what is regulated and what not, and how.  New openings are arising out of the shift in this line.  In additional, medical devices are no longer just ‘devices’; Software as a Medical Device (SaMD) is a whole...

To understand the current usage and future potential of liquid biopsy, we brought together experts from a range of disciplines to answer the following question: What is the current and future clinical utility of liquid biopsy based testing in oncology?

I’ve just got back to the office from a very interesting workshop looking to address the challenge of delivering rapid microbial testing in cell and gene products...

The new General Data Protection Regulation (GDPR) that will become law in May requires users to give consent for the collection of their sensitive personal data through a formal agreement rather than an assumption of...